Hereditary hemorrhagic telangiectasia
Drug research and approvals for hereditary hemorrhagic telangiectasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 17 studies of hereditary hemorrhagic telangiectasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Bevacizumab in the Treatment of HHTNCT07828015 · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts May 1, 2025
- Body Donation in HHTNCT07826845 · Not applicable · University Hospital, Essen · starts Oct 1, 2025
- A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic…NCT07743671 · Phase 3 · Vaderis Therapeutics AG · starts Nov 2, 2026
- DIAG723 in Adults With Hereditary Hemorrhagic TelangiectasiaNCT07623525 · Phase 1 / Phase 2 · Diagonal Therapeutics, Inc. · starts Jun 4, 2026
- Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)NCT07601425 · Phase 1 / Phase 2 · Atavistik Bio, Inc · starts Jul 27, 2026
- Quality of Life in Pediatric Participants With HHTNCT07474428 · Not reported · Ashley Nelson · starts Sep 1, 2026
- Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound DeviceNCT07414446 · Not applicable · St. Antonius Hospital · starts Jan 7, 2026
- Immunological Effects of Iron Supplementation in HHT DiseaseNCT07111598 · Not applicable · Hospices Civils de Lyon · starts Sep 24, 2025
- Institutional Registry of Rare DiseasesNCT06573723 · Not reported · Hospital Italiano de Buenos Aires · starts Jul 1, 2024
Phase 3 4
- BevacizumabVascular endothelial growth factor A inhibitor
- Tranexamic acidPlasminogen inhibitor
- PropranololBeta-1 adrenergic receptor antagonist
- MupirocinIsoleucyl-tRNA synthetase inhibitor
Phase 2 7
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TimololBeta-1 adrenergic receptor antagonist
- NintedanibPlatelet-derived growth factor receptor inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- TamoxifenEstrogen receptor alpha modulator
- OctreotideSomatostatin receptor agonist
Phase 1 or earlier 1
How its trials ended
82 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 44% met their primary endpoint, 19% missed it and 38% stopped early.
- Completed, result not reported4150%
- Ongoing1822%
- Met its primary endpoint79%
- Status unknown79%
- Stopped: other or unclear45%
- Missed its primary endpoint34%
- Stopped: sponsor or business decision22%
| Jun 9, 2025 | BMPRII: ALK1 bispecific clustering agonist antibodyTreatment of hereditary hemorrhagic telangiectasia | Diagonal Therapeutics | Designated |
| Dec 7, 2022 | 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)…Treatment of Hereditary Hemorrhagic Telangiectasia | Vaderis Therapeutics AG | Designated |
| Oct 12, 2022 | BevacizumabTreatment of hereditary hemorrhagic telangiectasia | Laboratoires Delbert SAS | Designated |
| Oct 9, 2019 | PazopanibTreatment of hereditary hemorrhagic telangiectasia | HHT Foundation International (d/b/a Cure HHT) | Designated |
| Jul 19, 2017 | ThalidomideTreatment of hereditary hemorrhagic telangiectasia | PlumeStars s.r.l. | Designated |
| Oct 21, 2010 | BevacizumabTreatment of hereditary hemorrhagic telangiectasia | Terence M. Davidson, MD | Designated |
| Aug 20, 2010 | Raloxifene hydrochlorideTreatment of hereditary hemorrhagic telangiectasia | Consejo Superior de Investigaciones Cientificas | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA